There are many things that cause a stock to move: acquisition rumors, news stories (both positive and negative), earnings releases, analyst upgrades/downgrades, ETF-forced …
In a research report sent to investors today, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Gilead Sciences (NASDAQ:GILD) with a …
Gilead Sciences (NASDAQ: GILD) dropped roughly 10% in morning trading on Wednesday, February 4th following the announcement of its fourth quarter 2014 earnings results the …
J.P.
Piper Jaffray’s healthcare analyst Joshua Schimmer is weighing in on Gilead Sciences’ (NASDAQ:GILD), after the company reported a solid fourth-quarter performance led by the HCV franchise, but conservatively guided below …
In a research report sent to investors today, Needham analyst Alan Carr reiterated a Buy rating on Gilead Sciences (NASDAQ:GILD) with a price target …
Needham’s healthcare analyst Alan Carr weighed in this morning with a few insights on Gilead Sciences (NASDAQ:GILD), as the company is scheduled to report its …
Deutsche Bank analyst Robyn Karnauskas came out today with an update on Gilead Sciences (NASDAQ:GILD), following the news that Anthem Inc. (NYSE:ANTM) chose GILD’s hepatitis C drug …
